molecular pharmacology -...

12
DiseasesCentral nervous system (Brain, retina, and spinal cord) Investigate pathology of diseases Generate animal disease model Evaluate effect of drug Stroke, mental illnesses, and Amyotrophic lateral sclerosis Glaucoma and Age-related Muscular dystrophy and Spinal muscular atrophy using iPS cells Molecular Pharmacology Zebrafish Mouse Common Marmoset Animals Themes Staffs Research of mental illnesses using several behavioral tests Analysis of the optic nerve denaturation using PET/MRI A non-invasive retina section scan The establishment of iPS cells derived from a human patient and differentiation instruction Pharmacometrics using iPS cells derived from the patients T2WI FA images of DTI 3 weeks 4 weeks L R L R L R Cerebral ischemia and hemorrhage model ALS model mice Study to be mediator of Death Valley considering Innovative drug development Professor Hideaki Hara Associate Proof. Masamitsu Shimazawa Assistant Professor Shinsuke Nakamura

Upload: phamngoc

Post on 17-Jun-2019

219 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Molecular Pharmacology - gifu-pu.ac.jpsv1.gifu-pu.ac.jp/lab/seitaikinou/files/2014/03/5c4d522a033564007ffb4183e55ad91d.pdf · Study to be mediator of Death Valley considering Innovative

Diseases:Central nervous system

(Brain, retina, and spinal cord)

・Investigate pathology of diseases

・Generate animal disease model

・Evaluate effect of drug

Stroke, mental illnesses, and

Amyotrophic lateral sclerosis

Glaucoma and Age-related

macular degeneration

Muscular dystrophy and Spinal

muscular atrophy using iPS cells

Molecular Pharmacology

Zebrafish

Mouse

Common Marmoset

AnimalsThemesStaffs

Research of mental illnesses

using several behavioral tests

Analysis of the optic nerve denaturation

using PET/MRI

A non-invasive

retina section scan

The establishment of iPS cells

derived from a human patient

and differentiation instruction

Pharmacometrics using iPS cells

derived from the patients

T2WI

FA images of DTI3 weeks 4 weeks

LR LR LR

Cerebral ischemia and

hemorrhage model

ALS model mice

Study to be mediator of Death Valley

considering Innovative drug development

Professor

Hideaki Hara

Associate Proof.

Masamitsu Shimazawa

Assistant Professor

Shinsuke Nakamura

Page 2: Molecular Pharmacology - gifu-pu.ac.jpsv1.gifu-pu.ac.jp/lab/seitaikinou/files/2014/03/5c4d522a033564007ffb4183e55ad91d.pdf · Study to be mediator of Death Valley considering Innovative

45 MembersStaffs

Hideaki Hara

Professor

Masamitsu Shimazawa

Associate Professor

Shinsuke Nakamura

Assistant Professor

Yoshiko Iwata

Secretary

Stroke (5 persons)

Mental illness (7 persons)

Neurodegenerative disease

(4 persons)

in vitro (10 persons)

CNS

Research 2 persons D2、B6、B5 1 person

iPS cell (5 persons)

D3、D2、D1、M2、B6、B5、B4 1 person

D3、B6、B5、B4 1 person

D2、 D1、 M2、B5、B4 1 person

D3、M1 1 person B6 2 persons

D4、D3、M2、M1、B4 1 person

Research 3 persons

D2、M2、B6 1person M1、B4 2 persons

Retina

Neuroprotection (4 persons)

Angiogenesis (5 persons)

Page 3: Molecular Pharmacology - gifu-pu.ac.jpsv1.gifu-pu.ac.jp/lab/seitaikinou/files/2014/03/5c4d522a033564007ffb4183e55ad91d.pdf · Study to be mediator of Death Valley considering Innovative

Brief introduction

Established in 1932

Students 800

Staffs 100

Hideaki HARA, PhD., R.Ph.

Vice President

Molecular Pharmacology,

Gifu Pharmaceutical University

Gifu Pharmaceutical

University

Page 4: Molecular Pharmacology - gifu-pu.ac.jpsv1.gifu-pu.ac.jp/lab/seitaikinou/files/2014/03/5c4d522a033564007ffb4183e55ad91d.pdf · Study to be mediator of Death Valley considering Innovative

Where we are

Japan

Gifu Pref.

Page 5: Molecular Pharmacology - gifu-pu.ac.jpsv1.gifu-pu.ac.jp/lab/seitaikinou/files/2014/03/5c4d522a033564007ffb4183e55ad91d.pdf · Study to be mediator of Death Valley considering Innovative

Scenic Gifu Prefecture

North part of Gifu

(Japanese Alps)

Gifu City

Gifu-jyo Castle

fireworks at

Nagara river

Cormorant fishing

Takayama Festival

Nagara

river

Nobunaga Oda

(Samurai lord)

Page 6: Molecular Pharmacology - gifu-pu.ac.jpsv1.gifu-pu.ac.jp/lab/seitaikinou/files/2014/03/5c4d522a033564007ffb4183e55ad91d.pdf · Study to be mediator of Death Valley considering Innovative

From BSc1 to BSc3

Mitahora Campus

Page 7: Molecular Pharmacology - gifu-pu.ac.jpsv1.gifu-pu.ac.jp/lab/seitaikinou/files/2014/03/5c4d522a033564007ffb4183e55ad91d.pdf · Study to be mediator of Death Valley considering Innovative

From BSc4 to BSc6,

MSc, PhD

HeadquartersBuilt in 2009

Page 8: Molecular Pharmacology - gifu-pu.ac.jpsv1.gifu-pu.ac.jp/lab/seitaikinou/files/2014/03/5c4d522a033564007ffb4183e55ad91d.pdf · Study to be mediator of Death Valley considering Innovative

School of Medicine

Gifu University Hospital

School of Veterinary Sciences

Animal hospital

Headquarters

GPU’s Pharmacy

School of Engineering

GPU and Gifu Univ.

Page 9: Molecular Pharmacology - gifu-pu.ac.jpsv1.gifu-pu.ac.jp/lab/seitaikinou/files/2014/03/5c4d522a033564007ffb4183e55ad91d.pdf · Study to be mediator of Death Valley considering Innovative

Our sciences and drug development

STEP 1 STEP 4 STEP 5STEP 2 STEP 3

Drug

screening

Preclinical

test

Target

validationPMS &

Practice

Clinical

trials

Pharm & Med Chem

Pharm Synth Chem

Pharmacognosy

Natural Resources

Molecular biology

Biochemistry

Pharmacology

Microbiol & Immunol

Hyg Chem & Toxicol

Clin Pharmaceutics

Med Therapeutics

Mol Pharmacology

Clin Pharmacy studies

Community Pharmacy

Drug Information

Pharmacy Practice

& social science

PharmaceuticsRadiochem

Global Regulatory

SciencePham Engineering

Pham Physical Chem

Pham Analytical Chem

Organic Chemistry

name of lab

Page 10: Molecular Pharmacology - gifu-pu.ac.jpsv1.gifu-pu.ac.jp/lab/seitaikinou/files/2014/03/5c4d522a033564007ffb4183e55ad91d.pdf · Study to be mediator of Death Valley considering Innovative

Generic name(application)Brand

nameCompany

On the

Market

Aminopropylon

(anti-inflammatory analgesic)Obelon

Nippon

Shinyaku1958

Ethyl piperidinoacetylaminobenzoate

(gastritis treatment)Sulcain

Nippon

Shinyaku1967

Emorfazone

(anti-inflammatory analgesic)Pentoil SANDOZ 1982

Tranilast (anti-allergic drug) RizabenKISSEI

Pharma1984

Bucolome (anti-gout agents) ParamidinASKA

Pharma1989

Suplatast Tosilate (anti-allergic drug) IPDTAIHO

Pharma1995

Representative drugs developed by GPU

Page 11: Molecular Pharmacology - gifu-pu.ac.jpsv1.gifu-pu.ac.jp/lab/seitaikinou/files/2014/03/5c4d522a033564007ffb4183e55ad91d.pdf · Study to be mediator of Death Valley considering Innovative

External Funds

Rank University Funds (¥)/ researcher

1 Univ. Tokyo 16,516,277

2 Kyoto Univ. 13,789,541

3 Tokyo Inst. Tech 12,110,037

.

.

.

.

29Fukushima Pref.

Univ.3,877,636

30 GPU 3,798,321

31 Nagasaki Univ. 3,732,452

#30 out of approx. 800 universities !

Our strength !

From the 2015 University ranking report (Asahi Newspaper)

36,000US$

Page 12: Molecular Pharmacology - gifu-pu.ac.jpsv1.gifu-pu.ac.jp/lab/seitaikinou/files/2014/03/5c4d522a033564007ffb4183e55ad91d.pdf · Study to be mediator of Death Valley considering Innovative

Grants-in aid from MEXT (government)

Rank university Grant (¥)/ researcher

1 Univ. Tokyo 9,567,953

2 Kyoto Univ. 7,530,962

3 Tokyo Inst. Tech 6,509,543

4 Osaka Univ. 6,069,458

5 Nagoya Univ. 6,022,415

.

.

.

20 Tsukuba Univ. 2,665,961

21 GPU 2,640,000

22 Hiroshima Univ. 2,621,118

#21 out of all 800 universities

Our strength !

From the 2015 University ranking report (Asahi Newspaper)

24,000US$

80,000US$

/resarcher

Total